AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech (NYSE American: AIM) has released its latest CEO Corner segment featuring CEO Thomas Equels. The segment, now available on the company's website, provides a comprehensive corporate update and focuses on the development progress of Ampligen, the company's lead product candidate, particularly in pancreatic cancer treatment.
The update includes details about recent scientific advancements and the company's strategic direction in advancing Ampligen's development program.
AIM ImmunoTech (NYSE American: AIM) ha pubblicato il suo ultimo segmento "CEO Corner" con il CEO Thomas Equels. Il video, ora disponibile sul sito aziendale, offre un aggiornamento completo sulla società e si concentra sui progressi dello sviluppo di Ampligen, il candidato principale dell'azienda, in particolare nel trattamento del cancro al pancreas.
L'aggiornamento presenta dettagli sui recenti avanzamenti scientifici e sulla direzione strategica dell'azienda nello sviluppo del programma di Ampligen.
AIM ImmunoTech (NYSE American: AIM) ha publicado su último segmento "CEO Corner" con el director ejecutivo Thomas Equels. El segmento, ya disponible en la página web de la compañía, ofrece una actualización corporativa completa y se centra en los avances en el desarrollo de Ampligen, el principal candidato a producto de la empresa, especialmente en el tratamiento del cáncer de páncreas.
La actualización incluye detalles sobre los avances científicos recientes y la dirección estratégica de la empresa para impulsar el programa de desarrollo de Ampligen.
AIM ImmunoTech (NYSE American: AIM)가 최고경영자(CEO) 토마스 이퀼스(Thomas Equels)가 출연한 최신 "CEO Corner" 영상을 공개했습니다. 해당 영상은 현재 회사 웹사이트에서 시청할 수 있으며, 회사 전반에 대한 포괄적인 업데이트와 함께 주요 파이프라인 후보물질인 Ampligen의 개발 진행 상황, 특히 췌장암 치료 분야에의 적용에 중점을 두고 있습니다.
이번 업데이트에는 최근 과학적 진전 사항과 Ampligen 개발 프로그램을 추진하기 위한 회사의 전략적 방향성에 관한 내용이 포함되어 있습니다.
AIM ImmunoTech (NYSE American: AIM) a publié son dernier segment « CEO Corner » avec le PDG Thomas Equels. Le segment, désormais disponible sur le site de l'entreprise, propose une mise à jour complète de la société et se concentre sur les progrès du développement de Ampligen, le principal candidat médicament de l'entreprise, en particulier pour le traitement du cancer du pancréas.
La mise à jour présente des détails sur les avancées scientifiques récentes et sur l'orientation stratégique de la société pour faire progresser le programme de développement d'Ampligen.
AIM ImmunoTech (NYSE American: AIM) hat sein neuestes "CEO Corner"-Segment mit CEO Thomas Equels veröffentlicht. Das Segment, das jetzt auf der Unternehmenswebseite verfügbar ist, bietet ein umfassendes Unternehmensupdate und legt den Fokus auf die Entwicklungsfortschritte von Ampligen, dem wichtigsten Produktkandidaten des Unternehmens, insbesondere in der Behandlung von Bauchspeicheldrüsenkrebs.
Das Update enthält Details zu den jüngsten wissenschaftlichen Fortschritten und zur strategischen Ausrichtung des Unternehmens bei der Weiterentwicklung des Ampligen-Programms.
- None.
- None.
Tom Equels, CEO of AIM ImmunoTech provides a corporate update and reiterates focus on driving Ampligen forward in pancreatic cancer
OCALA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels provides a “state of the union” corporate update and discusses the recent scientific progress made with lead product candidate, Ampligen.
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Publication of data, and pre-clinical and clinical success seen to date, does not guarantee that Ampligen will be approved for commercial treatment in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@jtcir.com
FAQ
When was the latest AIM ImmunoTech CEO Corner segment released?
What topics does AIM ImmunoTech CEO Thomas Equels discuss in the latest CEO Corner?
Where can investors access AIM ImmunoTech's CEO Corner segment?
What is the main focus of AIM ImmunoTech's development program?
